Auris Medical Holding AG (EARS) was Reiterated by Needham to “Buy” while Lowering the Price Target of the company shares to $ 5 from a previous price target of $11 . Needham advised their investors in a research report released on Aug 19, 2016.
On the company’s financial health, Auris Medical Holding AG reported $-0.25 EPS for the quarter, based on the information available during the earnings call on Aug 18, 2016. Analyst had a consensus estimate of $-0.25.During the same quarter in the previous year, the company posted $-0.34 EPS.
Auris Medical Holding AG opened for trading at $4.45 and hit $5.45 on the upside on Wednesday, eventually ending the session at $5.35, with a gain of 39.32% or 1.51 points. The heightened volatility saw the trading volume jump to 32,05,285 shares. Company has a market cap of $184 M.
Auris Medical Holding AG is a holding company. The Company is a development-stage biopharmaceutical company. The Company’s advanced product candidate is AM-101 for acute inner ear tinnitus. It is also developing AM-111 for acute inner ear hearing loss. Its product candidates are injected under local anesthesia into the middle ear by a technique called intratympanic or i.t. injection. The Company is also engaged in preclinical studies of AM-102 and AM-123. AM-101 is formulated in a biocompatible gel. AM-111 contains a synthetic D-form peptide (D-JNKI-1) that protects sensorineural structures in the inner ear from stress-induced damage. AM-111 is being developed for the treatment of autoimmune sensorineural hearing loss (ASNHL).